OncRef

Clinical Trial: NCT03117049

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Ono Pharmaceutical Co., Ltd.
Information Provided By:Ono Pharmaceutical Co., Ltd.
Last Update Posted:2024-05-06

Study Overview

Brief Summary

The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-naïve subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation in a multicenter, randomized, double-blind study.

Official Title

A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Conditions

Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: ONO-4538
  • Drug: Carboplatin
  • Drug: Paclitaxel
  • Drug: Bevacizumab
  • Drug: Placebo

Other Study ID Numbers

  • ONO-4538-52

Start Date (Actual)

2017-06-13

Primary Completion Date (Actual)

2020-02-10

Study Completion Date (Actual)

2023-12-04

Enrollment (Actual)

550

Study Type

Interventional

Phase

Phase 3